Paper Details

  1. Home
  2. Paper Details

Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.

Author: Aguiar-BujandaDavid, AndrésRaquel, AntónAntonio, BermejoBegoña, CarrascoEva, ChacónJose I, CruzJosefina, GuerreroÁngel, JaraCarlos, Lopez-TarruellaSara, MartínMiguel, MartínezPurificación, MirallesJuan J, MuñozMontserrat, PolonioÓscar, RamosManuel, Rodríguez-LescureÁlvaro, Ruiz-BorregoManuel, SantaballaAna, ServitjaSonia, ÁlvarezIsabel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A study of 1,617 patients with high-risk early breast cancer (EBC) showed that at 5 and 10 years, invasive disease-free survival (iDFS) rates were 75.2% and 57.0%, respectively. Distant disease-free survival (dDFS) and overall survival (OS) rates at 5 years were 77.4% and 88.8%, and the respective figures at 10 years were 59.7% and 70.9%. The data suggests that new therapies are needed for these patients.
Paper Details　
Original Abstract of the Article :
PURPOSE: The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to the monarchE trial to put into context the potential benefit of abemaciclib. METHODS: HR-positive...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361852/

データ提供：米国国立医学図書館（NLM）

A Long-Term Look at High-Risk Breast Cancer Treatment: Evaluating the Potential of Abemaciclib

The treatment landscape for breast cancer is constantly evolving, with new drugs and treatment strategies emerging all the time. This research examines the long-term outcomes of patients with high-risk early breast cancer (EBC) who received standard adjuvant therapies. The researchers compared the outcomes of these patients to those in the monarchE trial, which investigated the addition of abemaciclib to standard therapies. This analysis provides a valuable perspective on the potential benefits of abemaciclib in treating high-risk EBC and highlights the need for further research to fully understand its long-term impact. It's like exploring a vast desert, looking for new paths and opportunities to navigate and overcome challenges.

Abemaciclib: A Promising Addition to Breast Cancer Treatment

This research suggests that abemaciclib could potentially improve outcomes for patients with high-risk early breast cancer. However, longer-term follow-up is necessary to fully evaluate its efficacy and safety.

The Ongoing Search for Better Treatments

Breast cancer research continues to advance, with researchers constantly striving to develop more effective and less toxic therapies. This study emphasizes the importance of ongoing research and clinical trials to refine our understanding of breast cancer treatment and provide patients with the best possible care.

Dr. Camel's Conclusion

The fight against breast cancer is a challenging but rewarding journey, much like navigating a vast desert. This research sheds light on the potential of abemaciclib to improve outcomes for patients with high-risk EBC. It's like discovering a hidden oasis in the desert, offering a potential haven for those who are facing this challenging condition. We must continue to explore new horizons in breast cancer research, driven by a commitment to finding more effective and less toxic treatments.

Date :
  1. Date Completed 2023-07-24
  2. Date Revised 2023-07-24
Further Info :

Pubmed ID

37338729

DOI: Digital Object Identifier

PMC10361852

Related Literature

Article Analysis
・Effects of abemaciclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.